Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan.
Int J Gynaecol Obstet. 2011 Feb;112(2):135-9. doi: 10.1016/j.ijgo.2010.08.016. Epub 2010 Dec 4.
To evaluate the outcomes of patients with stage IB1-IIA cervical adenocarcinoma treated by various modalities in order to formulate a better treatment strategy.
The impact of various treatment modalities on the prognosis of 258 patients with stage IB1-IIA cervical adenocarcinoma was investigated. The therapeutic modalities included radical surgery (n=174); radical surgery followed by adjuvant radiation therapy (RT), such as RT alone or concurrent chemo-radiotherapy (CCRT) (n=46); or primary RT or CCRT (n=38).
As compared with patients in the surgery-only group, patients with 1 postoperative major risk who underwent surgery followed by RT or CCRT had a significantly higher likelihood of disease relapse (2.3-fold, P=0.041) and disease-related death (2.9-fold, P=0.014). The likelihood of recurrence (P=0.32) and death (P=0.58) did not differ between patients who underwent adjuvant RT or CCRT for 1 major risk factor and those who underwent primary RT or CCRT. By contrast, patients with more than 1 major risk factor had a higher likelihood of disease recurrence (2.9-fold, P=0.037) and disease-related death (3.4-fold, P=0.051) than those who underwent primary RT or CCRT.
Radical surgery is recommended for patients with stage IB1-IIA cervical adenocarcinomas without contraindications. Those with more than 1 postoperative pathologic risk factor had the worst prognosis despite adjuvant RT or CCRT.
评估不同治疗方式对 IB1 期至 IIA 期宫颈腺癌患者结局的影响,以制定更好的治疗策略。
本研究纳入了 258 例 IB1 期至 IIA 期宫颈腺癌患者,分析了不同治疗方式对其预后的影响。治疗方式包括根治性手术(n=174)、根治性手术后辅助放疗(如单纯放疗或同步放化疗)(n=46),或单纯放疗或同步放化疗(n=38)。
与单纯手术组相比,术后存在 1 项主要危险因素且行手术加放疗或同步放化疗的患者疾病复发(风险比 2.3,P=0.041)和疾病相关死亡(风险比 2.9,P=0.014)的风险显著更高。对于术后存在 1 项主要危险因素的患者,接受辅助放疗或同步放化疗与单纯行放疗或同步放化疗相比,其复发(P=0.32)和死亡(P=0.58)的风险并无差异。相比之下,存在超过 1 项主要危险因素的患者疾病复发(风险比 2.9,P=0.037)和疾病相关死亡(风险比 3.4,P=0.051)的风险均高于单纯行放疗或同步放化疗的患者。
对于无手术禁忌证的 IB1 期至 IIA 期宫颈腺癌患者,推荐行根治性手术。尽管术后接受了辅助放疗或同步放化疗,但存在多个术后病理危险因素的患者预后最差。